RxDoctor Payments Data

Mark Ratchford, DO

Family Medicine · Portage, PANPI 1669479101

Payments from drug & device makers

$874in general payments, 2019–2025

Across 72 payments — averaging $12.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$260
  • GSK$169
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$133
  • Biogen$116
  • Johnson & Johnson$90
  • Lilly USA, LLC$33
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$874 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$698
Medicare patients
22
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$218,221
JardianceEmpagliflozin200$215,167
EliquisApixaban226$189,329
Humira(Cf) PenAdalimumab25$186,939
RybelsusSemaglutide88$123,597
TrulicityDulaglutide92$102,509
XareltoRivaroxaban76$94,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$59,919
Breo ElliptaFluticasone/Vilanterol113$51,930
ProliaDenosumab24$40,933
MyrbetriqMirabegron55$34,339
Atorvastatin Calcium1,297$22,437
LinzessLinaclotide29$21,816
JanuviaSitagliptin Phosphate20$18,113
Rosuvastatin Calcium552$13,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$260$341,818252 claims
GSKTrelegy Ellipta, Breo Ellipta$169$111,849185 claims
Lilly USA, LLCTrulicity$33$102,50992 claims
Johnson & JohnsonXarelto$90$94,53476 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Portage

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →